表紙
市場調查報告書
商品編碼
975546

自動注射器的全球市場 (∼2025年): 各疾病區分 (類風濕性關節炎、多發性硬化症、過敏性反應、心血管疾病、糖尿病)、類型 (拋棄式、可重複使用)、給藥途徑 (皮下、肌肉內)、終端用戶 (醫院)

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of administration (Subcutaneous, Intramuscular), End User (Hospital) - Global Forecast to 2025

出版日期: | 出版商: MarketsandMarkets | 英文 177 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球自動注射器的市場規模在預測期間內預計以17.9%的年複合成長率發展,從2020年的460億美元,成長到2025年1049億美元的規模。對象疾病的增加,過敏性反應的發病率上升,偏好自我給藥的趨勢,可用性,法規當局的批准數量的增加,非專利版的可用性,有利的償付,政府支援,技術的進步,生技藥品的專利到期等要素預計促進該市場的成長。同時,偏好口服糖尿病藥物和鼻腎上腺素噴霧等替代途徑的趨勢預計妨礙市場進一步成長。

本報告提供全球自動注射器的市場調查,市場定義和概要,價值鏈,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,市場規模的變化、預測,零組件、疾病區分、類型、給藥途徑、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • COVID-19的影響
  • 平均銷售價格
  • 價值鏈分析
  • 生態系統分析

第6章 產業考察

  • 產業趨勢

第7章 市場分析、預測:各疾病種類

  • 類風濕性關節炎
  • 糖尿病
  • 多發性硬化症
  • 過敏性反應
  • 其他

第8章 市場分析、預測:各類型

  • 拋棄式注射器
  • 可重複使用注射器

第9章 市場分析、預測:各給藥途徑

  • 皮下注射
  • 肌肉內注射

第10章 市場分析、預測:各終端用戶

  • 居家醫療
  • 醫院、診所
  • 門診病人診療

第11章 市場分析、預測:各地區、主要國家

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他
  • 南美
  • 中東、非洲

第12章 企業評估矩陣

  • 市場佔有率分析
  • 供應商dive
  • SME、Start-Ups:競爭領導製圖

第13章 競爭情形

  • 產品系列矩陣
  • 地區的評估
  • R&D費
  • 競爭情形、趨勢

第14章 企業簡介

  • ABBVIE INC.
  • AMGEN
  • ELI LILLY AND COMPANY
  • MYLAN
  • YPSOMED
  • BECTON, DICKINSON AND COMPANY
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON (J&J)
  • TEVA PHARMACEUTICAL INDUSTRIES
  • ANTARES PHARMA, INC.
  • MERCK KGAA
  • MERIDIAN MEDICAL TECHNOLOGIES, INC. (A PFIZER COMPANY)
  • F. HOFFMANN-LA ROCHE
  • BESPAK
  • BAYER AG
  • BRISTOL-MYERS SQUIBB COMPANY
  • SHL MEDICAL
  • HASELMEIER
  • OWEN MUMFORD
  • RAVIMED
  • MEDECA PHARMA AB

第15章 附錄

目錄
Product Code: MD 6494

The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices.

"The rheumatoid arthritis segment accounted for the largest share of the autoinjectors market in 2020"

Based on therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapies (cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest market share of autoinjectors market. The large share of this segment is mainly due to the high prevalence of rheumatoid arthritis.

"The subcutaneous segment is projected to grow at the highest CAGR during the forecast period"

Based on route of administration, the autoinjectors market is segmented into intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anemia, and cancer. The subcutaneous segment is projected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

"North America accounted for the largest share of the autoinjectors market in 2020."

The autoinjectors market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and the Middle East & Africa. North America was the largest regional market for autoinjectors. Growth in the North American market is majorly driven by factors such as the rising incidence of anaphylaxis and the presence of favorable reimbursements. Moreover, the US and Canada are developed economies with high awareness and adoption rates for advanced devices such as autoinjectors, which is beneficial for market growth. Furthermore, other microeconomic indicators such as rising healthcare expenditures, high affordability rate, and the improving regulatory scenario are also major factors contributing to market growth.

  • By Company: Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
  • By Designation: C-level Executives: 25%, Directors: 55%, and Others: 20%
  • By Region: North America: 40%, Europe: 25%, APAC: 20%, LATAM: 10% and MEA: 5%

Some of the key players in the autoinjectors market are AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany), Meridian Medical Technologies, Inc. (US), Roche Diagnostics (Switzerland), Bespak (UK), Bayer (Germany), SHL Medical (Switzerland), Haselmeier (Switzerland), Owen Mumford (UK), Ravimed (Poland), Medeca Pharma AB (Sweden), Cambridge Consultants Ltd. (UK), Flex (US), SMC Ltd. (US), and Promius Pharma (US). The study includes an in-depth competitive analysis of these key players in the autoinjectors market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:

The market study covers the autoinjectors market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by therapy, type, route of administration, end users and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the autoinjectors market and its subsegments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders understand the pulse of the market and provide information on key market drivers, restraints, opportunities and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION & SCOPE
  • 1.3 MARKETS COVERED
    • FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION
  • 1.4 YEARS CONSIDERED FOR THE STUDY
  • 1.5 CURRENCY
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2019)
    • FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2019)
    • FIGURE 8 SUPPLY-SIDE ANALYSIS: AUTOINJECTORS MARKET (2019)
    • FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE AUTOINJECTORS MARKET (2019)
    • FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE AUTOINJECTORS MARKET (2020-2025)
  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 COVID-19 HEALTH ASSESSMENT
  • 2.7 COVID-19 ECONOMIC ASSESSMENT
  • 2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 12 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • FIGURE 13 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY

    • FIGURE 14 AUTOINJECTORS MARKET, BY THERAPY, 2020 VS. 2025 (USD MILLION)
    • FIGURE 15 AUTOINJECTORS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 16 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD MILLION)
    • FIGURE 17 AUTOINJECTORS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
    • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE AUTOINJECTORS MARKET

4 PREMIUM INSIGHTS

  • 4.1 AUTOINJECTORS MARKET OVERVIEW
    • FIGURE 19 GROWING PREVALENCE OF TARGETED THERAPIES AND RISING PREFERENCE FOR SELF-ADMINISTRATION OF DRUGS TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: AUTOINJECTORS MARKET, BY THERAPY AND COUNTRY (2020)
    • FIGURE 20 RHEUMATOID ARTHRITIS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020
  • 4.3 AUTOINJECTORS MARKET, BY REGION, 2020-2025
    • FIGURE 21 NORTH AMERICA WILL CONTINUE TO DOMINATE THE AUTOINJECTORS MARKET IN THE FORECAST PERIOD
  • 4.4 AUTOINJECTORS MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 23 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing prevalence of targeted therapies
    • FIGURE 24 CHINA: TOTAL DIABETIC POPULATION FROM 2010 TO 2045
      • 5.2.1.2 Rising incidence of anaphylaxis
      • 5.2.1.3 Increasing number of regulatory approvals
    • TABLE 1 RECENT APPROVALS OF AUTOINJECTOR DEVICES ACROSS THE GLOBE
      • 5.2.1.4 Availability of generic versions of autoinjectors
      • 5.2.1.5 Favorable reimbursements and government support
      • 5.2.1.6 Ease of use increasing the preference for self-administration
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Alternative drug delivery modes
      • 5.2.2.2 Research, development, and launch of oral diabetic agents and oral insulin
      • 5.2.2.3 Development of nasal epinephrine sprays
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Patent expiry of biologics to drive the demand for biosimilars
    • TABLE 2 PATENT EXPIRY OF KEY BIOLOGICS
      • 5.2.3.2 Need to limit patient visits and physical contact
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Development of autoinjectors for multiple drug viscosities
      • 5.2.4.2 Lack of proper training for using autoinjectors
  • 5.3 COVID-19 IMPACT ON THE AUTOINJECTORS MARKET
  • 5.4 AVERAGE SELLING PRICE TRENDS
    • TABLE 3 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 25 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS (2019)
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 26 ECOSYSTEM: AUTOINJECTORS MARKET (2019)

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 INDUSTRY TRENDS
    • 6.2.1 ADVANCEMENTS IN AUTOINJECTOR DESIGN
    • 6.2.2 WEARABLE AUTOINJECTORS
    • 6.2.3 CONNECTED AUTOINJECTOR DEVICES

7 AUTOINJECTORS MARKET, BY THERAPY

  • 7.1 INTRODUCTION
    • TABLE 4 AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
  • 7.2 RHEUMATOID ARTHRITIS
    • 7.2.1 INCREASING INCIDENCE OF RA HAS BOOSTED THE ADOPTION OF AUTOINJECTORS
    • TABLE 5 AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.3 DIABETES
    • 7.3.1 LARGE PATIENT POPULATION TO STIMULATE THE DEMAND FOR AUTOINJECTORS DURING THE FORECAST PERIOD
    • FIGURE 27 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20-79 YEARS), 2019 VS. 2030 VS. 2045
    • TABLE 6 AUTOINJECTORS MARKET FOR DIABETES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.4 MULTIPLE SCLEROSIS
    • 7.4.1 INFLUX OF GENERICS IS EXPECTED TO NEGATIVELY IMPACT MARKET GROWTH DURING THE FORECAST PERIOD
    • FIGURE 28 NUMBER OF PEOPLE WITH MS (PER 100,000) - WHO REGIONS
    • TABLE 7 AUTOINJECTORS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.5 ANAPHYLAXIS
    • 7.5.1 INCREASING PREVALENCE OF FOOD ALLERGIES TO DRIVE THE UPTAKE OF AUTOINJECTORS
    • TABLE 8 AUTOINJECTORS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.6 OTHER THERAPIES
    • TABLE 9 AUTOINJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.7 IMPACT OF COVID-19 ON THE THERAPEUTIC APPLICATIONS OF AUTOINJECTORS

8 AUTOINJECTORS MARKET, BY TYPE

  • 8.1 INTRODUCTION
    • TABLE 10 COMPARISON OF DISPOSABLE & REUSABLE AUTOINJECTORS
    • TABLE 11 AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • 8.2 DISPOSABLE AUTOINJECTORS
    • 8.2.1 DISPOSABLE AUTOINJECTORS ARE CONVENIENT FOR PATIENTS WITH REDUCED DEXTERITY OR VISUAL IMPAIRMENTS
    • TABLE 12 DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 8.3 REUSABLE AUTOINJECTORS
    • 8.3.1 REUSABLE AUTOINJECTORS ARE MORE ECONOMICAL AS COMPARED TO DISPOSABLE AUTOINJECTORS
    • TABLE 13 REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

9 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
    • TABLE 14 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
  • 9.2 SUBCUTANEOUS
    • 9.2.1 GROWING NUMBER OF PRODUCT APPROVALS BY REGULATORY BODIES WILL SUPPORT THE GROWTH OF THIS MARKET SEGMENT
    • TABLE 15 SUBCUTANEOUS AUTOINJECTORS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 9.3 INTRAMUSCULAR
    • 9.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES MEDICATION TO BE ABSORBED QUICKLY-A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 16 EXAMPLES OF INTRAMUSCULAR AUTOINJECTORS
    • TABLE 17 INTRAMUSCULAR AUTOINJECTORS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

10 AUTOINJECTORS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 18 AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 10.2 HOME CARE SETTINGS
    • 10.2.1 HOME CARE THERAPIES ARE COST-EFFECTIVE COMPARED TO TREATMENTS IN HOSPITALS-A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 19 AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 10.3 HOSPITALS & CLINICS
    • 10.3.1 HIGH USAGE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS & CLINICS WILL DRIVE MARKET GROWTH
    • TABLE 20 AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 10.4 AMBULATORY CARE SETTINGS
    • 10.4.1 INCREASING NUMBER OF PATIENTS IN AMBULATORY CARE SETTINGS TO DRIVE THE DEMAND FOR AUTOINJECTORS
    • TABLE 21 AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2018-2025 (USD MILLION)

11 AUTOINJECTORS MARKET, BY REGION

  • 11.1 REGIONAL COVID-19 IMPACT: SUMMARY
  • 11.2 INTRODUCTION
    • FIGURE 29 AUTOINJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • TABLE 22 AUTOINJECTORS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 11.3 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: AUTOINJECTORS MARKET SNAPSHOT
    • TABLE 23 NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 24 NORTH AMERICA: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 25 NORTH AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 26 NORTH AMERICA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 27 NORTH AMERICA: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.1 US
      • 11.3.1.1 The US is the largest market for autoinjectors in North America
    • TABLE 28 AUTOINJECTORS APPROVED BY THE FDA, 2017-2019
    • TABLE 29 US: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 30 US: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 31 US: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 32 US: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.2 CANADA
      • 11.3.2.1 Rising prevalence of chronic diseases to drive the market growth
    • TABLE 33 CANADA: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 34 CANADA: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 35 CANADA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 36 CANADA: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.4 EUROPE
    • FIGURE 31 EUROPE: AUTOINJECTORS MARKET SNAPSHOT
    • TABLE 37 EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 38 EUROPE: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 39 EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 40 EUROPE: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 41 EUROPE: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.1 GERMANY
      • 11.4.1.1 Germany is the largest market for autoinjectors in Europe
    • TABLE 42 GERMANY: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 43 GERMANY: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 44 GERMANY: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 45 GERMANY: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.2 UK
      • 11.4.2.1 The UK has the highest rate of allergic conditions globally-a key factor expected to boost the market growth
    • TABLE 46 UK: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 47 UK: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 48 UK: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 49 UK: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.3 FRANCE
      • 11.4.3.1 Rising geriatric population to support market growth
    • TABLE 50 FRANCE: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 51 FRANCE: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 52 FRANCE: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 53 FRANCE: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.4 ITALY
      • 11.4.4.1 Improving economic conditions and rising per capita income to propel market growth
    • TABLE 54 ITALY: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 55 ITALY: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 56 ITALY: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 57 ITALY: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.5 SPAIN
      • 11.4.5.1 Favorable reimbursement scenario coupled with the rising prevalence of chronic diseases to support market growth
    • TABLE 58 SPAIN: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 59 SPAIN: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 60 SPAIN: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 61 SPAIN: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.6 REST OF EUROPE
    • TABLE 62 ROE: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 63 ROE: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 64 ROE: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 65 ROE: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.5 ASIA PACIFIC
    • FIGURE 32 ASIA PACIFIC: AUTOINJECTORS MARKET SNAPSHOT
    • TABLE 66 ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.5.1 JAPAN
      • 11.5.1.1 High adoption of autoinjectors and approval of several injectable devices to boost the market growth
    • TABLE 71 JAPAN: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 72 JAPAN: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 73 JAPAN: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 74 JAPAN: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.5.2 CHINA
      • 11.5.2.1 Food allergies and anaphylaxis have become a major public health burden in China
    • TABLE 75 CHINA: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 76 CHINA: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 77 CHINA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 78 CHINA: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.5.3 INDIA
      • 11.5.3.1 Increasing burden of chronic diseases such as diabetes and CVD is expected to drive the demand for autoinjectors in India
    • TABLE 79 INDIA: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 80 INDIA: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 81 INDIA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 82 INDIA: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.5.4 ROAPAC
    • TABLE 83 ROAPAC: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 84 ROAPAC: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 85 ROAPAC: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 86 ROAPAC: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.6 LATIN AMERICA
    • 11.6.1 RISING ELDERLY POPULATION IN COUNTRIES SUCH AS BRAZIL AND MEXICO TO SUPPORT MARKET GROWTH
    • TABLE 87 LATIN AMERICA: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 88 LATIN AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 89 LATIN AMERICA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 90 LATIN AMERICA: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.7 MIDDLE EAST & AFRICA
    • 11.7.1 IMPLEMENTATION OF FAVORABLE REFORMS IN AFRICA AS WELL AS MIDDLE EASTERN COUNTRIES TO DRIVE MARKET GROWTH
    • TABLE 91 MEA: AUTOINJECTORS MARKET, BY THERAPY, 2018-2025 (USD MILLION)
    • TABLE 92 MEA: AUTOINJECTORS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 93 MEA: AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 94 MEA: AUTOINJECTORS MARKET, BY END USER, 2018-2025 (USD MILLION)

12 COMPANY EVALUATION MATRIX

  • 12.1 MARKET SHARE ANALYSIS
    • FIGURE 33 AUTOINJECTORS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
  • 12.2 VENDOR DIVE
    • 12.2.1 STARS
    • 12.2.2 EMERGING LEADERS
    • 12.2.3 PERVASIVE PLAYERS
    • 12.2.4 EMERGING COMPANIES
    • FIGURE 34 AUTOINJECTORS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
  • 12.3 COMPETITIVE LEADERSHIP MAPPING FOR SMALL & MEDIUM-SIZED ENTERPRISES (SMES)/STARTUPS
    • 12.3.1 PROGRESSIVE COMPANIES
    • 12.3.2 STARTING BLOCKS
    • 12.3.3 RESPONSIVE COMPANIES
    • 12.3.4 DYNAMIC COMPANIES
    • FIGURE 35 AUTOINJECTORS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
    • FIGURE 36 KEY DEVELOPMENTS IN THE AUTOINJECTORS MARKET
    • FIGURE 37 GROWTH STRATEGY MATRIX
  • 13.2 PRODUCT PORTFOLIO MATRIX
    • 13.2.1 THERAPY
  • 13.3 AUTOINJECTORS MARKET: GEOGRAPHICAL ASSESSMENT
    • FIGURE 38 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN THE AUTOINJECTORS MARKET (2019)
  • 13.4 AUTOINJECTORS MARKET: R&D EXPENDITURE
    • FIGURE 39 R&D EXPENDITURE OF KEY PLAYERS IN THE AUTOINJECTORS MARKET (2019)
  • 13.5 COMPETITIVE SITUATIONS AND TRENDS
    • 13.5.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 95 PRODUCT LAUNCHES & APPROVALS (2018-2020)
    • 13.5.2 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
    • TABLE 96 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS (2018-2020)
    • 13.5.3 ACQUISITIONS
    • TABLE 97 ACQUISITIONS (2020)
    • 13.5.4 EXPANSIONS
    • TABLE 98 EXPANSIONS (2018-2020)
    • 13.5.5 OTHER DEVELOPMENTS
    • TABLE 99 OTHER DEVELOPMENTS (2019-2020)

14 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MNM View, and Strategic Overview)**

  • 14.1 ABBVIE INC.
    • FIGURE 40 ABBVIE INC.: COMPANY SNAPSHOT (2019)
  • 14.2 AMGEN
    • FIGURE 41 AMGEN: COMPANY SNAPSHOT (2019)
  • 14.3 ELI LILLY AND COMPANY
    • FIGURE 42 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
  • 14.4 MYLAN
    • FIGURE 43 MYLAN: COMPANY SNAPSHOT (2019)
  • 14.5 YPSOMED
    • FIGURE 44 YPSOMED: COMPANY SNAPSHOT (2019)
  • 14.6 BECTON, DICKINSON AND COMPANY
    • FIGURE 45 BD: COMPANY SNAPSHOT (2019)
  • 14.7 GLAXOSMITHKLINE PLC
    • FIGURE 46 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
  • 14.8 JOHNSON & JOHNSON (J&J)
    • FIGURE 47 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
  • 14.9 TEVA PHARMACEUTICAL INDUSTRIES
    • FIGURE 48 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2019)
  • 14.10 ANTARES PHARMA, INC.
    • FIGURE 49 ANTARES PHARMA: COMPANY SNAPSHOT (2019)
  • 14.11 MERCK KGAA
    • FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2019)
  • 14.12 MERIDIAN MEDICAL TECHNOLOGIES, INC. (A PFIZER COMPANY)
    • FIGURE 51 PFIZER: COMPANY SNAPSHOT (2019)
  • 14.13 F. HOFFMANN-LA ROCHE
    • FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
  • 14.14 BESPAK
    • FIGURE 53 CONSORT MEDICAL PLC: COMPANY SNAPSHOT (2019)
  • 14.15 BAYER AG
    • FIGURE 54 BAYER AG: COMPANY SNAPSHOT (2019)
  • 14.16 BRISTOL-MYERS SQUIBB COMPANY
    • FIGURE 55 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2019)
  • 14.17 SHL MEDICAL
  • 14.18 HASELMEIER
  • 14.19 OWEN MUMFORD
  • 14.20 RAVIMED
  • 14.21 MEDECA PHARMA AB

*Details on Business Overview, Products Offered, Recent Developments, MNM View, and Strategic Overview might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 15.2 DISCUSSION GUIDE
  • 15.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.4 AVAILABLE CUSTOMIZATIONS
  • 15.5 RELATED REPORTS
  • 15.6 AUTHOR DETAILS